$2.7 Billion is the total value of Artal Group S.A.'s 108 reported holdings in Q4 2018. The portfolio turnover from Q3 2018 to Q4 2018 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| OCX | Exit | ONCOCYTE CORPORATION | $0 | – | -150,000 | -100.0% | -0.01% | – |
| LIFE | Exit | ATYR PHARMA INC | $0 | – | -500,000 | -100.0% | -0.01% | – |
| UBX | Exit | UNITY BIOTECHNOLOGY INC | $0 | – | -50,000 | -100.0% | -0.02% | – |
| NVAX | Exit | NOVAVAX INC | $0 | – | -500,000 | -100.0% | -0.02% | – |
| ADVM | Exit | ADVERUM BIOTECHNOLOGIES INC | $0 | – | -400,000 | -100.0% | -0.06% | – |
| NTLA | Exit | INTELLIA THERAPEUTICS INC | $0 | – | -90,000 | -100.0% | -0.07% | – |
| SYBX | Exit | SYNLOGIC INC | $0 | – | -200,000 | -100.0% | -0.07% | – |
| CNAT | Exit | CONATUS PHARMACEUTICALS INC | $0 | – | -500,000 | -100.0% | -0.08% | – |
| FLEX | Exit | FLEX LTDord | $0 | – | -250,000 | -100.0% | -0.08% | – |
| XENE | Exit | XENON PHARMACEUTICALS INC | $0 | – | -250,000 | -100.0% | -0.09% | – |
| ELAN | Exit | ELANCO ANIMAL HEALTH INC | $0 | – | -100,000 | -100.0% | -0.09% | – |
| LJPC | Exit | LA JOLLA PHARMACEUTICAL CO | $0 | – | -200,000 | -100.0% | -0.10% | – |
| LOGM | Exit | LOGMEIN INC | $0 | – | -65,000 | -100.0% | -0.15% | – |
| AXDX | Exit | ACCELERATE DIAGNOSTICS INCcall | $0 | – | -500,000 | -100.0% | -0.30% | – |
| BABA | Exit | ALIBABA GROUP HLDG LTDcall | $0 | – | -100,000 | -100.0% | -0.43% | – |
| C | Exit | CITIGROUP INCcall | $0 | – | -250,000 | -100.0% | -0.47% | – |
| XBI | Exit | SPDR SERIES TRUSTcall | $0 | – | -200,000 | -100.0% | -0.50% | – |
| TSRO | Exit | TESARO INCcall | $0 | – | -500,000 | -100.0% | -0.51% | – |
| TSRO | Exit | TESARO INC | $0 | – | -800,000 | -100.0% | -0.81% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-02-11
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AGENUS INC | 42 | Q3 2023 | 1.9% |
| IRONWOOD PHARMACEUTICALS INC | 42 | Q3 2023 | 0.3% |
| ALNYLAM PHARMACEUTICALS INC | 37 | Q3 2023 | 5.1% |
| LEXICON PHARMACEUTICALS INC | 34 | Q3 2023 | 20.6% |
| AMICUS THERAPEUTICS INC | 30 | Q3 2023 | 2.7% |
| BEIGENE LTD | 28 | Q3 2023 | 7.4% |
| BK OF AMERICA CORP | 28 | Q1 2021 | 4.3% |
| SAGE THERAPEUTICS INC | 28 | Q2 2023 | 1.9% |
| AGIOS PHARMACEUTICALS INC | 28 | Q2 2020 | 1.1% |
| NEKTAR THERAPEUTICS | 27 | Q2 2020 | 1.3% |
View Artal Group S.A.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| WEIGHT WATCHERS INTERNATIONAL INC | February 13, 2015 | 29,443,300 | 51.9% |
View Artal Group S.A.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-03-25 |
| 4 | 2024-03-13 |
| 4 | 2024-02-29 |
| 13F-HR | 2024-02-09 |
| 13F-HR | 2023-11-13 |
| 4 | 2023-10-16 |
| 13F-HR | 2023-08-11 |
| 4 | 2023-06-22 |
| 3 | 2023-06-15 |
| 4 | 2023-06-05 |
View Artal Group S.A.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.